This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente. Abbott’s BVS restores blood flow by starting a clogged vessel and offering support to the vessel until the device dissolves within around two years, leaving patients with a treated vessel free of a long term metallic implant. The device received CE Mark authorization in europe for the treating coronary artery disease and can be under clinical investigation in a number of countries around the world. The initial affected individual in Japan was treated in the ABSORB EXTEND clinical trial by Shigeru Saito, M.D., director, Cardiology and Catheterization Laboratories, and vice president, Shonan Kamakura Medical center, Kanagawa, Japan.Pregnant patients were those who were pregnant during onset of influenza symptoms. Postpartum patients were those with an onset of influenza symptoms through the first 14 days after delivery. We estimated the maternal mortality ratio for California for the time defined by the dates of indicator onset in all patients one of them analysis: April 3 through August 5, 2009. The amount of live births in this population in 2009 2009 was estimated on the basis of the number of live births in this population through the same period in 2008 . This investigation was reviewed by the California Committee for the Protection of Human being Topics.